JPRN-jRCT2011230045进行中（未招募）3 期
An Open-Label, Safety Study for Previously Treated Vatiquinone (PTC743) Subjects With Inherited Mitochondrial Disease
Vinay Penematsa0 个研究点目标入组 10 人开始时间: 2023年11月5日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •Participants with inherited mitochondrial disease including Leigh syndrome, Alpers syndrome, mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS), myoclonic epilepsy with ragged-red fibers (MERRF), pontocerebellar hypoplasia type 6 (PCH6), or other mitochondrial disease who participated in a previous vatiquinone clinical study or treatment plan.
- •- Women of childbearing potential must have a negative pregnancy test at screening/baseline and agree to abstinence or the use of at least 1 of the highly effective forms of contraception as specified in the protocol (with a failure rate of <1% per year when used consistently and correctly). Highly effective contraception or abstinence must be continued for the duration of the study, and for up to 30 days after the last dose of study drug.
- •- Fertile men who are sexually active with women of childbearing potential and who have not had a vasectomy, must agree to use a barrier method of birth control during the study and for up to 30 days after the last dose of study drug.
排除标准
- •- Current participation in any other interventional study.
- •- Pregnancy or breast feeding.
研究者
相似试验
暂停
不适用
Safety and efficacy of baby diaper pantCTRI/2020/10/028193The Himalaya Drug Company40
已完成
不适用
An Safety Study to evaluate the effectiveness of Kalimera hair oil on Human hair health for hair Growth, Hair Strength, Hair Lustrous and Dandruff preventioCTRI/2019/05/019022BioVein Innovations Solutions Private Limited50
已完成
3 期
An open-label study to assess the safety, tolerability and multiple-dose phamacokinetics of AA4500 0.58 mg in subjects with Dupuytren's contractures.ACTRN12610001045000Auxilium Phamaceuticals, Inc.12
进行中（未招募）
不适用
An open label study to determine the safety and tolerability oftwo dose escalation treatment regimens with an oral, delayed release preparation of nicotine in patients with stable ulcerative colitismaintained by steroid therapy. - NDlcerative colitisMedDRA version: 9.1Level: LLTClassification code 10009900Term: Colitis ulcerativeEUCTR2006-006052-35-ITS.L.A. PHARMA (UK) LTD
已完成
1 期
A Phase 1, Open-Label Study Evaluating the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of SM07883, a Novel DYRK1a Inhibitor, Following Oral Administration to Healthy SubjectsNeurological - Alzheimer's diseaseAlzheimer's DiseaseACTRN12619000327189Samumed Pacific Pty Ltd28